<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01711021</url>
  </required_header>
  <id_info>
    <org_study_id>N25-006</org_study_id>
    <nct_id>NCT01711021</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety &amp; Efficacy of d-Amphetamine Transdermal System Compared to Placebo in Children &amp; Adolescents With ADHD</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Crossover, Laboratory Classroom Study to Evaluate the Safety and Efficacy of d-Amphetamine Transdermal Drug Delivery System (d-ATS) Compared to Placebo in Children and Adolescents With ADHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noven Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Noven Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate safety and efficacy of d-Amphetamine Transdermal System for the&#xD;
      treatment of Attention Deficit Hyperactivity Disorder in children and adolescents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a four-week screening period, a 3-day wash-out period (if&#xD;
      applicable), a five-week open-label, step-wise dose optimization period and two-week double&#xD;
      blind randomized crossover treatment period with weekly classroom assessments and a safety&#xD;
      follow-up by telephone 7 - 10 days after last dose of study drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in total SKAMP Scores</measure>
    <time_frame>Measured weekly during a two-week double-blind treatment period</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>d-Amphetamine Transdermal System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>d-Amphetamine Transdermal System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo patch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>d-Amphetamine Transdermal System</intervention_name>
    <description>Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.</description>
    <arm_group_label>d-Amphetamine Transdermal System</arm_group_label>
    <other_name>d-Amphetamine</other_name>
    <other_name>Amphetamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo patch</intervention_name>
    <description>Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.</description>
    <arm_group_label>Placebo patch</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>Sham treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gender: Male or female;&#xD;
&#xD;
          -  Age: Between 6 &amp;17 years of age, inclusive;&#xD;
&#xD;
          -  Race: All eligible;&#xD;
&#xD;
          -  Females of child-bearing potential must agree to practice a clinically accepted method&#xD;
             of contraception during the study &amp; for at least one month prior to study dosing &amp; one&#xD;
             month following completion of the study. Acceptable contraceptive methods include&#xD;
             abstinence, oral contraception, surgical sterilization (bilateral tubal ligation,&#xD;
             bilateral oophorectomy or hysterectomy), intrauterine device, or diaphragm in addition&#xD;
             to spermicidal foam &amp; condom on male partner, or systemic contraception [e.g. Norplant&#xD;
             System];&#xD;
&#xD;
          -  Must meet Diagnostic &amp; Statistical Manual of Mental Disorders, 4th edition - Text&#xD;
             Revision criteria for a primary diagnosis of ADHD combined, predominately hyperactive&#xD;
             impulsive type, or predominately inattentive type;&#xD;
&#xD;
          -  The screening &amp; baseline visit ADHD-RS-IV total score must be 90% or greater relative&#xD;
             to the general population of children by age &amp; gender;&#xD;
&#xD;
          -  Must be able to wear a patch for 9 hours. Parent or caregiver must be present to apply&#xD;
             &amp; remove the patches &amp; maintain the used &amp; unused patches in a secure controlled area&#xD;
             of the home;&#xD;
&#xD;
          -  Must be functioning at an age appropriate level intellectually as determined by an&#xD;
             intelligence quotient of ≥80 on the Wechsler Abbreviated Scale of Intelligence II™,&#xD;
             vocabulary &amp; matrix reasoning components;&#xD;
&#xD;
          -  Must have the ability to complete PERMP assessment;&#xD;
&#xD;
          -  Have parental consent &amp; written or verbal assent from the subject;&#xD;
&#xD;
          -  Subject &amp; parent(s)/caregiver are willing &amp; able to comply with all the protocol&#xD;
             requirements &amp; parent(s) or caregiver must be able to provide transportation for the&#xD;
             subject to &amp; from the analog classroom sessions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has blood pressure &amp; pulse outside the 95th percentile for age &amp; gender;&#xD;
&#xD;
          -  Is a known non-responder to amphetamine treatment;&#xD;
&#xD;
          -  Has a documented allergy, intolerance, or hypersensitivity to amphetamine;&#xD;
&#xD;
          -  Is currently taking an ADHD medication that is providing symptom control with no&#xD;
             residual impairment at home or school &amp; has acceptable tolerability &amp; adherence;&#xD;
&#xD;
          -  Has a recent history (within the past 6 months) of suspected substance abuse or&#xD;
             dependence disorder (including nicotine);&#xD;
&#xD;
          -  Has a history of seizures during the last 2 years (exclusive of infantile febrile&#xD;
             seizures), a tic disorder (exclusive of transient tic disorder), a current diagnosis&#xD;
             and/or a family history of Tourette's Disorder. Mild medication-induced tics are not&#xD;
             exclusionary;&#xD;
&#xD;
          -  Has any psychiatric disorder that could interfere with study participation or the&#xD;
             safety of the subject or other participants, such as conduct disorder or oppositional&#xD;
             defiant disorder with a history of prominent aggressive outbursts. Children meeting CD&#xD;
             or ODD but without prominent aggression will be allowed to enroll at the discretion of&#xD;
             the investigator;&#xD;
&#xD;
          -  Has Autism or Asperger's Disorder;&#xD;
&#xD;
          -  Has a family history (first degree relatives) of sudden cardiac death;&#xD;
&#xD;
          -  Has current controlled (requiring medication) or uncontrolled comorbid psychiatric&#xD;
             conditions such as post traumatic stress disorder, psychosis, bipolar illness, severe&#xD;
             obsessive compulsive disorder, severe depressive or severe anxiety disorder,&#xD;
             considered a suicide risk, has previously attempted suicide, has prior history of or&#xD;
             is currently demonstrating suicidal ideation;&#xD;
&#xD;
          -  Has a history of abnormal thyroid function;&#xD;
&#xD;
          -  Has BMI for age greater than 95th percentile per CDC BMI-for-gender specific charts;&#xD;
&#xD;
          -  Has a known history of symptomatic cardiovascular disease, advance arteriosclerosis,&#xD;
             structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities,&#xD;
             coronary artery disease, or other serious cardiac problems that may place them at&#xD;
             increased vulnerability to the sympathomimetic effects of a stimulant drug;&#xD;
&#xD;
          -  Has any skin abnormality present at the potential application site that is likely to&#xD;
             be aggravated by the study drug (i.e., infection, rash, atrophy, excessive fragility&#xD;
             or dryness, any cut or abrasion, or tattoo);&#xD;
&#xD;
          -  Has a history of hypersensitivity, allergy to topical medication, preparation, or&#xD;
             adhesive dressings;&#xD;
&#xD;
          -  Has concurrent chronic or significant acute illnesses (such as severe allergic&#xD;
             rhinitis or an infectious process requiring antibiotics, unless expected to resolve or&#xD;
             has resolved by Day 0) disability or any unstable medical condition that in the&#xD;
             investigator's opinion would lead to difficulty complying with the protocol&#xD;
             requirements;&#xD;
&#xD;
          -  Has used any investigational drug within 30 days of the screening visit;&#xD;
&#xD;
          -  Has a history of physical, sexual, or emotional abuse in the last year;&#xD;
&#xD;
          -  Has a medical history of Hepatitis A, B,C or HIV;&#xD;
&#xD;
          -  Has positive urine drug screen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Waxmonsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Not Affiliated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Children and Families</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 15, 2012</study_first_submitted>
  <study_first_submitted_qc>October 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2012</study_first_posted>
  <disposition_first_submitted>April 1, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 1, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 30, 2014</disposition_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

